Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 0.77 |
| ▸ | NPC1 | O15118 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | NAMPT | P43490 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108168 | 0.89 | KMT2A (0.81) | GSK3BRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12010919 | 0.83 | RAB9A (0.84) | GSK3BRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL22103783 | 0.81 | GSK3B (0.68) | GSK3BRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL107421 | 0.81 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL13126014 | 0.80 | RAB9A (0.73) | GSK3BRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20379676 | 0.80 | NAMPT (1.00) | GSK3BRAB9AALDH1A1NAMPT | |
| SCHEMBL1463242 | 0.80 | KMT2A (0.78) | GSK3BRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL1464690 | 0.79 | KMT2A (0.77) | GSK3BRAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL108370 | 0.78 | RAB9A (0.81) | GSK3BRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5327057 | 0.78 | MAPT (0.72) | GSK3BRAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919465-B1 | GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-1919465-B1 | GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20090124686-A1 | GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2009-05-14 | — | — | US | disclosed |
| US-20090124686-A1 | GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2009-05-14 | — | — | US | disclosed |
| US-20090124686-A1 | GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2009-05-14 | — | — | US | disclosed |
| WO-2007017145-A2 | GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| EP-1749523-A1 | GSK-3 inhibitors | Neuropharma, S.A. (ES) | 2007-02-07 | — | — | EP | disclosed |
| EP-1749523-A1 | GSK-3 inhibitors | Neuropharma, S.A. (ES) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124686-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885RAB9A 4073/4885NPC1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.